Clinical Trial Search

Primary: Number of Participants With a Catheter Associated Urinary Tract Infection (CAUTI) — 7; 6 Participants

Primary: Rate of Catheter-associated Urinary Tract Infection — 10; 12 infections per 1000 days

Primary: The Primary Efficacy Outcome of the Study is Response to Treatment Which Will be Assessed at the End of Therapy. Successful Response to Treatment is Defined as…

Primary: Rate of UTI While Colonized With E. Coli 83972. — 8.5 UTIs per 1000 patient-days

Primary: Infections Per 1,000 (CAUTI) Days — 0.8429 infection per 1,000 catheter days

Primary: Number of Central Venous Catheter Hubs With Internal Contamination — 42; 18; 39; 14 contaminated hubs

Primary: Occurrence of Symptomatic Urinary Tract Infections (UTIs) — 19; 20; 2; 0 participants — p=0.0383

Primary: Disinfecting Barrier Cap Compliance — 98.43 percentage of connector with compliance

Primary: Number of Participants With Appropriate Treatment — 31; 23 Participants — p=0.45

Primary: Number of Patients With a Major Cardiac Implantable Electronic Devices (CIED) Infection — 5; 6 Participants

Primary: Catheter-associated Venous Thrombosis — 3; 3 Participants

Primary: Urinary Tract Infection Rate — 24; 29 Participants — p=0.30

Primary: Number of Participants With Postoperative Healthcare Acquired Infections — 108; 116 Participants

Primary: Total Bacteria Count Change From Baseline and After 24 Hours. — -62519; 57448 CFU/mL — p=0.6250

Primary: Participants With Clinically-diagnosed and Treated UTI's. — 15; 30 participants

Primary: Clinical Response Within 48 Hours — 28 Participants

Primary: The Number of Catheter Related Bloodstream Infections (BSI) /1000 Catheter Days in Both Arms — 4.74; 4.72 BSIs /1000 catheter days — p=0.05

Primary: Total Number of MDRO (Multidrug Resistant Organisms) Isolated — 1299; 1732 Total Number of MDRO isolates — p=<0.05

Primary: Participants With Complications With Central Access Including Insertion — 14; 10 Participants — p=0.271

Primary: CLABSI and VAP Rates — 1.84; 2.42; 2.24; 2.47 events/1000 device days — p=<.05

Primary: Bacteraemia Rate — 2; 1 episodes — p=1.00

Primary: Rate of PICC Line Occlusions — 37 percentage of enrolled subjects

Primary: Number of Subjects With Shunt Infections — 14 participants

Primary: Total Number of Central Line Associated Blood Stream Infections (CLABSI) — 113; 84; 123; 109 infections

Primary: Clinical Response at Test of Cure (TOC) in Microbiological Modified Intent-to-treat (mMITT) Analysis Set — 6; 8; 129; 132 Participant

Primary: Urinary Tract Infection — 11; 12 UTI

Primary: Incidence of Nosocomial Infection — 15; 30 participants — p=0.049

Primary: Microbiological Response at the Test of Cure (TOC) Visit in the Microbiological Modified Intent-to-Treat (mMITT) Population — 83.1; 76.3 percentage of patients

Primary: Positive Blood Cultures (PBC's) Per 1,000 Central Venous Catheter (CVC)-Days — 0.28; 0.75 PBCs per 1,000 CVC-days

Primary: MRSA and VRE Clinical Cultures — 0.87; 0.79 Hazard Ratio (Intervention vs Baseline) — p=0.17